Angiogenesis-related signaling protein

"Angiogenesis-related signaling proteins" is not the name of a single molecule or receptor but rather refers collectively to a group of proteins involved in the regulation and execution of angiogenesis—the process by which new blood vessels form from pre-existing vasculature. This group includes growth factors, receptors, transcription factors, and enzymes that participate in complex signaling cascades. Key examples include vascular endothelial growth factor A (VEGF-A), its receptors VEGFR1/2/3, platelet-derived growth factor (PDGF), fibroblast growth factor (FGF), matrix metalloproteinases (MMPs), and others[1][2][3]. These molecules are central to physiological processes like wound healing and embryonic development but are also implicated in pathological conditions such as cancer progression, metastasis, chronic inflammation, and endometriosis[1][2][3]. Therapeutic strategies have been developed to target these pathways—most notably antiangiogenic agents that inhibit VEGF or its receptors—but "angiogenesis-related signaling proteins" itself is too broad and non-specific to be considered a canonical therapeutic target. Instead, individual components within this category serve as validated drug targets; examples include monoclonal antibodies against VEGF-A or tyrosine kinase inhibitors targeting VEGFRs[4][5]. Biomarkers used clinically often focus on levels of specific proangiogenic factors like circulating VEGF-A or gene expression signatures associated with response to antiangiogenic therapy[6].